John Stoltzfus, chief market strategist at Oppenheimer, told CNBC's "Power Lunch" an improvement in earnings will power the move.» Read More
"The Profit" host Marcus Lemonis discusses apologies in the workplace.
Discussing Goldman Sachs' warning on oil and where the commodity is headed, with Ken Sill, Global Hunter Securities.
Vertex Pharmaceuticals shares are halted as a panel of advisors to the FDA review the company's experiment treatment for Cystic Fibrosis. CNBC's Meg Tirrell reports.
Peter Kafka, Re/code, and Frank Louthan, Raymond James, discuss reasons for Verizon's purchase of AOL.
"The Profit" host Marcus Lemonis discusses the method of Holacracy following Zappos' adoption of the management plan.
Two Nepalese soldiers and 6 U.S. Marines were on board the helicopter declared missing in Nepal. CNBC's Sue Herera reports the helicopter had been supporting earthquake relief.
CNBC contributor Ron Insana says the Federal Reserve is likely to raise rates in 2015.
Daniel Morris, TIAA-CREF Asset Management, thinks there is more downside risk to the equity market than upside potential.
According to Mortgage News Daily, 4 percent is the new world order on the 30-Year fixed mortgage, reports CNBC's Diana Olick
How safe is your SUV? CNBC's Phil LeBeau reports results from the latest midsize SUV crash tests. "The Profit" host Marcus Lemonis, weighs in.
Democrats may have votes to block the trade bill debate. CNBC's John Harwood reports.
Discussing the impact the bond market may have on equities going forward, with Burns McKinney, NFJ Investment Group, and Mike Holland, Holland and Company.
CNBC's Bob Pisani dissects today's market action and the move on interest rates.
"The Profit" host Marcus Lemonis weighs in on Verizon's acquisition of AOL and whether it will help the company's delivery of ad technology and content.
CNBC's Rick Santelli reports on strong demand at the 3-year Treasury auction.
Marcus Lemonis, "The Profit" host, discusses this season's new shows which airs tonight at 10pm ET/PT.
Telecom giant Verizon announced Tuesday it will be buying AOL for $50 per share, or about $4.4 billion.
This company has raised $1 billion to develop the Holy Grail in drugs: Have the body's own cells churn out proteins to fight disease.
Two major research houses on Wall Street recommend getting rid of domestic stocks in favor of multinational names as the dollar weakens.
Some of the names on the move ahead of the open.